Compare Stocks

Date Range: 

 Rhythm PharmaceuticalsArcturus TherapeuticsTrillium TherapeuticsConstellation PharmaceuticalsMannKind
SymbolNASDAQ:RYTMNASDAQ:ARCTNASDAQ:TRILNASDAQ:CNSTNASDAQ:MNKD
Price Information
Current Price$22.12$31.80$9.59$20.80$4.29
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.81.61.71.21.4
Analysis Score3.43.13.53.43.5
Community Score2.62.62.92.42.2
Dividend Score0.00.00.00.00.0
Ownership Score2.51.71.70.00.8
Earnings & Valuation Score0.60.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$50.67$70.67$21.83$40.33$6.63
% Upside from Price Target129.05% upside122.22% upside127.67% upside93.91% upside54.43% upside
Trade Information
Market Cap$1.11 billion$836.98 million$988.09 million$996.61 million$1.07 billion
Beta1.573.012.272.82.28
Average Volume447,5571,084,2611,441,325462,3675,380,282
Sales & Book Value
Annual RevenueN/A$20.79 million$120,000.00N/A$63.04 million
Price / SalesN/A40.268,234.05N/A16.95
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.40 per share$1.70 per share($0.86) per share$8.23 per share($0.92) per share
Price / BookN/A18.71-11.15N/A-4.66
Profitability
Net Income$-140,730,000.00$-25,990,000.00$-41,620,000.00$-85,550,000.00$-51,900,000.00
EPS($3.86)($2.15)($1.38)($3.04)($0.27)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-506.70%N/AN/A-71.92%
Return on Equity (ROE)-55.21%-52.32%-70.00%-28.88%N/A
Return on Assets (ROA)-50.73%-33.21%-28.84%-24.98%-46.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.06%N/A0.05%N/A
Current Ratio13.24%11.21%22.44%15.81%0.63%
Quick Ratio13.25%11.21%22.44%15.81%0.58%
Ownership Information
Institutional Ownership Percentage88.43%74.33%67.46%N/A29.60%
Insider Ownership Percentage9.49%12.60%N/A10.60%1.09%
Miscellaneous
Employees90118N/A154240
Shares Outstanding50.21 million26.32 million103.03 million47.91 million249.07 million
Next Earnings Date8/2/2021 (Estimated)5/10/2021 (Confirmed)8/11/2021 (Estimated)5/10/2021 (Confirmed)5/12/2021 (Confirmed)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
MannKind Stock Is Believed To Be Significantly OvervaluedMannKind Stock Is Believed To Be Significantly Overvalued
gurufocus.com - May 9 at 12:43 AM
Analysts Say MannKind Corporation (NASDAQ:MNKD) Can Really Get to $8 in 12 MonthsAnalysts Say MannKind Corporation (NASDAQ:MNKD) Can Really Get to $8 in 12 Months
marketingsentinel.com - May 8 at 7:38 AM
MannKind (MNKD) Scheduled to Post Quarterly Earnings on WednesdayMannKind (MNKD) Scheduled to Post Quarterly Earnings on Wednesday
americanbankingnews.com - May 6 at 12:59 PM
MannKind Co. (NASDAQ:MNKD) Forecasted to Post FY2022 Earnings of ($0.15) Per ShareMannKind Co. (NASDAQ:MNKD) Forecasted to Post FY2022 Earnings of ($0.15) Per Share
americanbankingnews.com - May 6 at 11:12 AM
MannKind (NASDAQ:MNKD) Cut to Strong Sell at Zacks Investment ResearchMannKind (NASDAQ:MNKD) Cut to Strong Sell at Zacks Investment Research
marketbeat.com - May 6 at 2:18 AM
MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021 - Yahoo FinanceMannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021 - Yahoo Finance
finance.yahoo.com - May 5 at 1:17 PM
MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021
finance.yahoo.com - May 5 at 1:17 PM
Marshall & Sullivan Inc Buys iShares Russell 2000 ETF, Vanguard FTSE Emerging Markets ETF - GuruFocus.comMarshall & Sullivan Inc Buys iShares Russell 2000 ETF, Vanguard FTSE Emerging Markets ETF - GuruFocus.com
gurufocus.com - May 5 at 8:16 AM
MannKind Corporation (MNKD) investors to reap big returns againMannKind Corporation (MNKD) investors to reap big returns again
marketingsentinel.com - May 4 at 9:59 AM
Take A Look At This MannKind Corporation (NASDAQ:MNKD) Analysis Before You InvestTake A Look At This MannKind Corporation (NASDAQ:MNKD) Analysis Before You Invest
stocksregister.com - May 3 at 1:48 PM
Inhalers Market: Know about Impact of Covid-19 by Top Companies like – Orion Pharm, MannKind, Hovione, Merck, Aristopharma, Novartis, and more – Clark County Blog - Clark County BlogInhalers Market: Know about Impact of Covid-19 by Top Companies like – Orion Pharm, MannKind, Hovione, Merck, Aristopharma, Novartis, and more – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 1 at 1:51 PM
Global Diabetes Drug Therapy Market 2021 Regional Outlook – Abbott Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic – Jumbo News - Jumbo NewsGlobal Diabetes Drug Therapy Market 2021 Regional Outlook – Abbott Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic – Jumbo News - Jumbo News
jumbonews.co.uk - May 1 at 8:50 AM
Huge Demand of Anaphylaxis Market by 2026 | Impax Laboratories Inc., MannKind Corporation, ALK-Abelló, Lincoln Medical Ltd., Adamis Pharmaceutical Corporation - Clark County BlogHuge Demand of Anaphylaxis Market by 2026 | Impax Laboratories Inc., MannKind Corporation, ALK-Abelló, Lincoln Medical Ltd., Adamis Pharmaceutical Corporation - Clark County Blog
clarkcountyblog.com - April 30 at 7:25 PM
Medical Inhaler Market 2021 In-depth Analysis, Growth with Forecast 2025 : GSK, Novartis, AstraZeneca, Chiesi, Cipla, Boehringer Ingelheim, Mannkind, 3M, Mylan, Hovione, ResMed - Clark County BlogMedical Inhaler Market 2021 In-depth Analysis, Growth with Forecast 2025 : GSK, Novartis, AstraZeneca, Chiesi, Cipla, Boehringer Ingelheim, Mannkind, 3M, Mylan, Hovione, ResMed - Clark County Blog
clarkcountyblog.com - April 29 at 1:37 PM
Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline - Yahoo FinanceEarnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline - Yahoo Finance
finance.yahoo.com - April 28 at 2:46 PM
Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to DeclineEarnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline
finance.yahoo.com - April 28 at 2:46 PM
Receptor Life Sciences Announces Poster Presentations at the Respiratory Drug Delivery 2021 Conference - StreetInsider.comReceptor Life Sciences Announces Poster Presentations at the Respiratory Drug Delivery 2021 Conference - StreetInsider.com
streetinsider.com - April 27 at 8:48 AM
MannKind Reduces Debt by Nearly $50 Million - San Fernando Valley Business JournalMannKind Reduces Debt by Nearly $50 Million - San Fernando Valley Business Journal
sfvbj.com - April 26 at 7:21 PM
Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer - StreetInsider.comAntares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer - StreetInsider.com
streetinsider.com - April 26 at 9:19 AM
MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche - GlobeNewswireMannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche - GlobeNewswire
globenewswire.com - April 26 at 9:19 AM
MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third TrancheMannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
finance.yahoo.com - April 26 at 9:19 AM
Global Diabetes Mellitus Treatment Market Top Manufacturers Analysis by 2026: Novo Nordisk, Sanofi, MannKind, Bristol-Myers Squibb, AstraZeneca etc. – Clark County Blog - Clark County BlogGlobal Diabetes Mellitus Treatment Market Top Manufacturers Analysis by 2026: Novo Nordisk, Sanofi, MannKind, Bristol-Myers Squibb, AstraZeneca etc. – Clark County Blog - Clark County Blog
clarkcountyblog.com - April 25 at 1:16 PM
MNKD June 4th Options Begin Trading - NasdaqMNKD June 4th Options Begin Trading - Nasdaq
nasdaq.com - April 23 at 3:48 AM
MannKind (NASDAQ:MNKD) Stock Price Down 4.1%MannKind (NASDAQ:MNKD) Stock Price Down 4.1%
americanbankingnews.com - April 22 at 12:50 PM
Unlocking Growth Opportunity in MannKind Corporation (NASDAQ:MNKD)Unlocking Growth Opportunity in MannKind Corporation (NASDAQ:MNKD)
stocksregister.com - April 22 at 12:22 PM
Market Analysts see MannKind Corporation [MNKD] gaining to $2.50. Time to buy?Market Analysts see MannKind Corporation [MNKD] gaining to $2.50. Time to buy?
dbtnews.com - April 22 at 12:22 PM
DateCompanyBrokerageAction
3/9/2021Rhythm PharmaceuticalsMorgan StanleyBoost Price Target
1/27/2021Rhythm PharmaceuticalsStifel NicolausBoost Price Target
1/27/2021Rhythm PharmaceuticalsCanaccord GenuityBoost Price Target
1/27/2021Rhythm PharmaceuticalsLADENBURG THALM/SH SHBoost Price Target
11/30/2020Rhythm PharmaceuticalsBank of AmericaDowngrade
8/3/2020Rhythm PharmaceuticalsNeedham & Company LLCInitiated Coverage
1/8/2020Rhythm PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
9/25/2019Rhythm PharmaceuticalsCowenReiterated Rating
3/8/2021Arcturus TherapeuticsB. RileyLower Price Target
3/2/2021Arcturus TherapeuticsRoth CapitalLower Price Target
1/7/2021Arcturus TherapeuticsWells Fargo & CompanyInitiated Coverage
12/29/2020Arcturus TherapeuticsHC WainwrightDowngrade
12/29/2020Arcturus TherapeuticsRobert W. BairdDowngrade
12/29/2020Arcturus TherapeuticsBarclaysDowngrade
12/29/2020Arcturus TherapeuticsRaymond JamesDowngrade
12/14/2020Arcturus TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/14/2020Arcturus TherapeuticsSmith Barney CitigroupBoost Price Target
8/25/2020Arcturus TherapeuticsPiper SandlerInitiated Coverage
8/11/2020Arcturus TherapeuticsBrookline Capital ManagementReiterated Rating
4/29/2021Trillium TherapeuticsBloom BurtonUpgrade
4/26/2021Trillium TherapeuticsJonestradingReiterated Rating
4/20/2021Trillium TherapeuticsBenchmarkInitiated Coverage
11/18/2020Trillium TherapeuticsCraig HallumBoost Price Target
10/12/2020Trillium TherapeuticsEvercore ISIInitiated Coverage
9/9/2020Trillium TherapeuticsJMP SecuritiesBoost Price Target
4/7/2021Constellation PharmaceuticalsRoyal Bank of CanadaReiterated Rating
1/25/2021Constellation PharmaceuticalsBMO Capital MarketsUpgrade
9/24/2020Constellation PharmaceuticalsOppenheimerReiterated Rating
8/9/2020Constellation PharmaceuticalsJefferies Financial GroupReiterated Rating
2/13/2020Constellation PharmaceuticalsSunTrust BanksInitiated Coverage
3/11/2021MannKindSVB LeerinkBoost Price Target
2/24/2021MannKindBTIG ResearchBoost Price Target
11/5/2020MannKindCantor FitzgeraldReiterated Rating
6/15/2018MannKindMaxim GroupReiterated Rating
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.